BTIG analyst Ryan Zimmerman raised the firm’s price target on Organogenesis to $6 from $4 and keeps a Buy rating on the shares. The analyst cites the ceiling payment rates updated in Medicare Part B ASP drug pricing but notes that while the company’s PuraPly XT pricing is being impacted from LCD dynamics, the management’s reinstated guidance “matters more”.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ORGO: